EP2654763A4 - Use of marihuana and compounds therein for treating obesity - Google Patents

Use of marihuana and compounds therein for treating obesity

Info

Publication number
EP2654763A4
EP2654763A4 EP11850518.9A EP11850518A EP2654763A4 EP 2654763 A4 EP2654763 A4 EP 2654763A4 EP 11850518 A EP11850518 A EP 11850518A EP 2654763 A4 EP2654763 A4 EP 2654763A4
Authority
EP
European Patent Office
Prior art keywords
marihuana
compounds
treating obesity
obesity
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11850518.9A
Other languages
German (de)
French (fr)
Other versions
EP2654763A1 (en
Inventor
Strat Yann Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2654763A1 publication Critical patent/EP2654763A1/en
Publication of EP2654763A4 publication Critical patent/EP2654763A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
EP11850518.9A 2010-12-20 2011-10-11 Use of marihuana and compounds therein for treating obesity Withdrawn EP2654763A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2726085A CA2726085A1 (en) 2010-12-20 2010-12-20 User of marihuana and compounds therein for treating obesity
PCT/CA2011/001131 WO2012083414A1 (en) 2010-12-20 2011-10-11 Use of marihuana and compounds therein for treating obesity

Publications (2)

Publication Number Publication Date
EP2654763A1 EP2654763A1 (en) 2013-10-30
EP2654763A4 true EP2654763A4 (en) 2014-05-21

Family

ID=46312939

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11850518.9A Withdrawn EP2654763A4 (en) 2010-12-20 2011-10-11 Use of marihuana and compounds therein for treating obesity

Country Status (3)

Country Link
EP (1) EP2654763A4 (en)
CA (1) CA2726085A1 (en)
WO (1) WO2012083414A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
KR20220037666A (en) * 2020-09-18 2022-03-25 주식회사 유셀파마 Composition for preventing, alleviating or treating fatty liver disease comprising Cannabis sativa stem extract as effective component
KR102269820B1 (en) * 2021-01-18 2021-06-28 주식회사 네이처센스 Pharmaceutical composition comprising the extract of cannabis sativa as an effective ingredient for preventing or treating of obesity
KR102269823B1 (en) * 2021-01-18 2021-06-28 주식회사 네이처센스 A composition containing extract of cannabis sativ for preventing or treating metabolic syndrome-related diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094429A1 (en) * 2003-04-23 2004-11-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
WO2005007628A1 (en) * 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
WO2007138322A1 (en) * 2006-06-01 2007-12-06 Gw Pharma Limited New use for cannabinoid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1287859A (en) * 1999-09-15 2001-03-21 王莲凤 Traditional Chinese medicinal pill for removing blood stasis
CN101044877A (en) * 2007-04-18 2007-10-03 吴建生 Weight-reducing tea
GB2459637B (en) * 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
CN101513475A (en) * 2009-03-03 2009-08-26 杨秀花 Method for preparing antifat traditional Chinese medicine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094429A1 (en) * 2003-04-23 2004-11-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
WO2005007628A1 (en) * 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
WO2007138322A1 (en) * 2006-06-01 2007-12-06 Gw Pharma Limited New use for cannabinoid

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LE FOLL BERNARD ET AL: "Cannabis and [Delta]9-tetrahydrocannabinol (THC) for weight loss?", MEDICAL HYPOTHESES, vol. 80, no. 5, 2013, pages 564 - 567, XP028526291, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2013.01.019 *
LE STRAT Y ET AL: "Obesity and cannabis use: Results from 2 representative national surveys", 24 August 2011, AMERICAN JOURNAL OF EPIDEMIOLOGY 20111015 OXFORD UNIVERSITY PRESS GBR, VOL. 174, NR. 8, PAGE(S) 929 - 933, ISSN: 0002-9262, XP002723025 *
MOREIRA F A ET AL: "Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL ENDOCRINOLOGYAND METABOLISM, BAILLIERE TINDALL, LONDON, GB, vol. 23, no. 1, 1 February 2009 (2009-02-01), pages 133 - 144, XP025973977, ISSN: 1521-690X, [retrieved on 20090311], DOI: 10.1016/J.BEEM.2008.09.003 *
RODONDI N ET AL: "Marijuana Use, Diet, Body Mass Index, and Cardiovascular Risk Factors (from the CARDIA Study)", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, vol. 98, no. 4, 15 August 2006 (2006-08-15), pages 478 - 484, XP027909986, ISSN: 0002-9149, [retrieved on 20060815] *
See also references of WO2012083414A1 *
VEMURI ET AL: "Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome", PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 93, no. 4-5, 21 November 2007 (2007-11-21), pages 671 - 686, XP022534335, ISSN: 0031-9384, DOI: 10.1016/J.PHYSBEH.2007.11.012 *

Also Published As

Publication number Publication date
EP2654763A1 (en) 2013-10-30
CA2726085A1 (en) 2012-06-20
WO2012083414A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
IL282128A (en) Methods of treating overweight and obesity
HK1173654A1 (en) Therapeutic compounds and related methods of use
EP2603202A4 (en) Compositions and methods for treatment of taupathy
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
HUE047994T2 (en) Bardoxolone methyl for the treatment of obesity
HRP20170225T1 (en) Phosphaplatins and their use for treatment of cancers
EP2464227A4 (en) Compounds and methods of use thereof
HRP20181879T1 (en) Compounds for the treatment of obesity and methods of use thereof
EP2389171A4 (en) Use of pterosin compounds for treating diabetes and obesity
SG10201510568WA (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
EP2533635A4 (en) Compositions and methods for treating obesity and obesity-related conditions
EP2654763A4 (en) Use of marihuana and compounds therein for treating obesity
EP2608794A4 (en) Methods and compositions for preventing or treating obesity
EP2536342A4 (en) Intramedullary device and method of use
EP2406244A4 (en) Estrogenic compounds and their methods of use
ZA201304381B (en) Novel-19-nor-steroid and their use for treating progesterone-dependent conditions
EP2539463A4 (en) Markers for obesity and methods of use thereof
GB2500357B (en) Combination and composition for treating obesity
IL207966A0 (en) Compounds and methods of treating obesity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140425

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 36/185 20060101AFI20140414BHEP

Ipc: A61P 3/04 20060101ALI20140414BHEP

Ipc: A61K 31/05 20060101ALI20140414BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141125